X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Ultimovacs UV1, which is a hTERT inhibitor, is being evaluated in Phase II clinical trial studies in combination with Ipilimumab and Nivolumab in patients for the treatment of Unresectable or Metastatic Malignant Melanoma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 07, 2024
Details:
UV1 is an off-the-shelf cancer vaccine designed to induce a specific T cell response against telomerase. It is being evaluated in phase 2 clinical trials in combination with ipilimumab and nivolumab for treatment of patients with unresectable malignant pleural mesothelioma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 19, 2024
Details:
UV1 is an off-the-shelf cancer vaccine designed to induce a specific T cell response against telomerase. It is being evaluated in phase 2 clinical trials in combination with ipilimumab and nivolumab for treatment of patients with unresectable malignant pleural mesothelioma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 05, 2024
Details:
UV1 is a universal cancer vaccine designed to induce a specific T-cell response against telomerase. It is under phase 2 clinical development in combination with nivolumab and ipilimumab for the treatment of unresectable or metastatic malignant melanoma.
Lead Product(s): UV1,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 16, 2024
Details:
TENDU vaccine is a therapeutic peptide conjugate vaccine, which is under phase 1 clinical development for the treatment of patients with prostate cancer.
Lead Product(s): Tendu
Therapeutic Area: Oncology Product Name: Tendu
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase, being developed in combination with the checkpoint inhibitors ipilimumab and nivolumab in the treatment of patients with unresectable or metastatic malignant melanoma.
Lead Product(s): UV1,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 02, 2023
Details:
UV1 (telomerase inhibitor) in combination with ipilimumab and nivolumab is under phase 2 clinical development for first-line treatment of patients with metastatic malignant melanoma.
Lead Product(s): UV1,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 31, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase. UV1 has the potential to provide T cell support believed to be critical for triggering a strong anti-tumor immune response for the treatment of malignant melanoma.
Lead Product(s): UV1 Cancer Vaccine,Sargramostim,Ipilimumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase. UV1 has the potential to provide T cell support believed to be critical for triggering a strong anti-tumor immune response for the treatment of mesothelioma.
Lead Product(s): UV1 Cancer Vaccine,Ipilimumab,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 09, 2023
Details:
UV1 is a universal cancer vaccine designed to induce a specific T cell response against human telomerase. UV1 has the potential to provide T cell support believed to be critical for triggering a strong anti-tumor immune response for the treatment of head and neck cancer.
Lead Product(s): UV1,Sargramostim,Nivolumab
Therapeutic Area: Oncology Product Name: UV1
Highest Development Status: Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
